Analysts Set Expectations for OS Therapies Q1 Earnings

OS Therapies Inc (NYSE:OSTX) – Stock analysts at Brookline Capital Management issued their Q1 2025 EPS estimates for OS Therapies in a report released on Wednesday, April 2nd. Brookline Capital Management analyst K. Raja anticipates that the company will earn ($0.11) per share for the quarter. The consensus estimate for OS Therapies’ current full-year earnings is ($0.64) per share. Brookline Capital Management also issued estimates for OS Therapies’ Q1 2025 earnings at ($0.11) EPS, Q2 2025 earnings at ($0.11) EPS, Q2 2025 earnings at ($0.11) EPS, Q3 2025 earnings at ($0.10) EPS and Q4 2025 earnings at ($0.10) EPS.

A number of other equities research analysts have also recently commented on OSTX. Lake Street Capital initiated coverage on OS Therapies in a research note on Wednesday. They issued a “buy” rating and a $19.00 price objective for the company. D. Boral Capital restated a “buy” rating and set a $20.00 price target on shares of OS Therapies in a research note on Monday, March 31st. Finally, Maxim Group raised their price objective on shares of OS Therapies from $8.00 to $15.00 and gave the company a “buy” rating in a research note on Thursday, January 16th. Three equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus price target of $18.00.

OS Therapies Stock Performance

Shares of OSTX opened at $1.40 on Friday. OS Therapies has a one year low of $1.33 and a one year high of $7.00. The stock has a 50-day moving average of $1.77 and a 200-day moving average of $2.68.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in OS Therapies stock. Virtu Financial LLC bought a new position in shares of OS Therapies Inc (NYSE:OSTX) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 10,045 shares of the company’s stock, valued at approximately $28,000.

Insider Activity

In other news, major shareholder Shalom Auerbach sold 16,720 shares of the stock in a transaction dated Wednesday, January 15th. The shares were sold at an average price of $6.74, for a total value of $112,692.80. Following the completion of the sale, the insider now owns 2,531,211 shares in the company, valued at $17,060,362.14. This represents a 0.66 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Corporate insiders own 13.80% of the company’s stock.

OS Therapies Company Profile

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers.